Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GKOS Stock Forecast 2026-2027
$152.96
Current Price
$8.98B
Market Cap
Buy 14
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GKOS Price Targets
+11.1%
To High Target of $170.00
+5.9%
To Median Target of $162.00
-9.8%
To Low Target of $138.00
GKOS Price Momentum
+3.1%
1 Week Change
+21.1%
1 Month Change
+46.1%
1 Year Change
+35.5%
Year-to-Date Change
-0.8%
From 52W High of $154.12
+109.1%
From 52W Low of $73.16
📊 TOP ANALYST CALLS
Did GKOS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Glaukos is one of their latest high-conviction picks.
Latest GKOS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, GKOS has a bullish consensus with a median price target of $162.00 (ranging from $138.00 to $170.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $152.96, the median forecast implies a 5.9% upside. This outlook is supported by 14 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GKOS Analyst Ratings
14
Buy
0
Hold
0
Sell
GKOS Price Target Range
Low
$138.00
Average
$162.00
High
$170.00
Current: $152.96
Latest GKOS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GKOS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 6, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $168.00 |
| Jul 1, 2026 | Piper Sandler | Adam Maeder | Overweight | Reiterates | $165.00 |
| Jun 17, 2026 | Needham | Buy | Maintains | $N/A | |
| Jun 11, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jun 10, 2026 | BTIG | Buy | Reiterates | $N/A | |
| May 21, 2026 | BTIG | Buy | Maintains | $N/A | |
| May 20, 2026 | BTIG | Buy | Maintains | $N/A | |
| Apr 30, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Apr 30, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Apr 30, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Apr 30, 2026 | Needham | Buy | Maintains | $N/A | |
| Apr 30, 2026 | BTIG | Buy | Maintains | $N/A | |
| Feb 18, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 18, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 18, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Jan 28, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jan 22, 2026 | Stifel | Buy | Maintains | $N/A | |
| Jan 14, 2026 | Needham | Buy | Reiterates | $N/A | |
| Jan 2, 2026 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Jan 2, 2026 | BTIG | Buy | Reiterates | $N/A |
Glaukos Corporation (GKOS) Competitors
The following stocks are similar to Glaukos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Glaukos Corporation (GKOS) Financial Data
Glaukos Corporation has a market capitalization of $8.98B with a P/E ratio of -46.7x. The company generates $551.35M in trailing twelve-month revenue with a -34.3% profit margin.
Revenue growth is +41.2% quarter-over-quarter, while maintaining an operating margin of -13.2% and return on equity of -26.4%.
Valuation Metrics
Market Cap
$8.98B
Enterprise Value
$8.67B
P/E Ratio
-46.7x
PEG Ratio
-7.5x
Price/Sales
16.4x
Growth & Margins
Revenue Growth (YoY)
+41.2%
Gross Margin
+77.9%
Operating Margin
-13.2%
Net Margin
-34.3%
EPS Growth
+41.2%
Financial Health
Cash/Price Ratio
+3.1%
Current Ratio
5.4x
Debt/Equity
15.8x
ROE
-26.4%
ROA
-5.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Glaukos Corporation (GKOS) Business Model
About Glaukos Corporation
What They Do
Develops innovative ophthalmic medical technologies.
Business Model
The company generates revenue through the development and sale of innovative products aimed at treating glaucoma, corneal disorders, and retinal diseases. Their focus on micro-invasive glaucoma surgery (MIGS) devices allows them to provide alternatives to traditional invasive procedures, capturing market share in a critical healthcare segment.
Additional Information
Glaukos is instrumental in addressing significant unmet medical needs within ophthalmic healthcare, particularly in reducing intraocular pressure for glaucoma patients. Their commitment to improving patient outcomes and quality of life, along with their emphasis on expanding technological advancements, positions them as a leader in the ophthalmology market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,094
CEO
Mr. Thomas William Burns
Country
United States
IPO Year
2015
Website
www.glaukos.comGlaukos Corporation (GKOS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.
Jul 08, 2026
By Zacks Equity Research
Analyst Blog
Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?
Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.
Jun 29, 2026
By Indrajit Bandyopadhyay
Analyst Blog
Latest News
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
14 days ago
Quick Summary
Glaukos Corporation (NYSE: GKOS) has completed patient enrollment in its Phase 2 clinical study for GLK-321, an investigational treatment for Demodex blepharitis, utilizing its iLution drug-delivery platform.
Why It Matters
Completion of patient enrollment in a Phase 2 study for GLK-321 signals progress in Glaukos' pipeline, potentially leading to new revenue streams and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Glaukos is experiencing growth with iDose TR and is launching Epioxa in an underpenetrated market, though it faces risks from reimbursement issues and competition.
Why It Matters
Glaukos' growth potential from iDose TR and Epioxa could boost revenues, but reimbursement challenges and competition may impact profitability and market share.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Glaukos Corporation (NYSE: GKOS) will participate in the Stifel Virtual Ophthalmology Forum on May 26, 2026, and the William Blair 46th Annual Growth Stock Conference on June 2, 2026.
Why It Matters
Glaukos Corporation's participation in key investor conferences may enhance visibility, attract investor interest, and potentially influence stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
GKOS reported a 41% revenue increase in Q1, narrowed losses, and raised its 2026 outlook, driven by growth in glaucoma and corneal segments.
Why It Matters
GKOS's strong Q1 performance and improved outlook signal robust growth potential, likely boosting investor confidence and stock value in the ophthalmic sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Novocure and Glaukos outperformed Wall Street's first-quarter expectations, leading the Medical-Products industry group.
Why It Matters
Strong earnings from Novocure and Glaukos signal robust performance in the Medical-Products sector, potentially boosting investor confidence and influencing stock valuations.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
Glaukos Corporation (GKOS) held its Q1 2026 earnings call, discussing financial performance and strategic initiatives. Further details on earnings and forecasts are available in the transcript.
Why It Matters
Glaukos Corporation's Q1 2026 earnings call reveals key financial performance and strategic updates, influencing stock valuation and investment decisions in the ophthalmic device sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About GKOS Stock
What is Glaukos Corporation's (GKOS) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Glaukos Corporation (GKOS) has a median price target of $162.00. The highest price target is $170.00 and the lowest is $138.00.
Is GKOS stock a good investment in 2027?
According to current analyst ratings, GKOS has 14 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $152.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GKOS stock?
Wall Street analysts predict GKOS stock could reach $162.00 in the next 12 months. This represents a 5.9% increase from the current price of $152.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Glaukos Corporation's business model?
The company generates revenue through the development and sale of innovative products aimed at treating glaucoma, corneal disorders, and retinal diseases. Their focus on micro-invasive glaucoma surgery (MIGS) devices allows them to provide alternatives to traditional invasive procedures, capturing market share in a critical healthcare segment.
What is the highest forecasted price for GKOS Glaukos Corporation?
The highest price target for GKOS is $170.00 from at , which represents a 11.1% increase from the current price of $152.96.
What is the lowest forecasted price for GKOS Glaukos Corporation?
The lowest price target for GKOS is $138.00 from at , which represents a -9.8% decrease from the current price of $152.96.
What is the overall GKOS consensus from analysts for Glaukos Corporation?
The overall analyst consensus for GKOS is bullish. Out of 4 Wall Street analysts, 14 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $162.00.
How accurate are GKOS stock price projections?
Stock price projections, including those for Glaukos Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 5:46 AM UTC